Department of Biotechnology and Microbiology and IUCB, Dr Janaki Ammal Campus, Kannur University, Palayad, Thalassery, Kannur, Kerala, 670661, India.
Transdisciplinary Biology, Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram, Kerala, 695014, India.
Sci Rep. 2023 Jun 30;13(1):10644. doi: 10.1038/s41598-023-37613-z.
Mammalian lipoxygenases (LOXs) are involved in the biosynthesis of mediators of anaphylactic reactions and have been implicated in cell maturation, the pathogenesis of bronchial asthma, atherosclerosis, rheumatoid arthritis, cardiovascular diseases, Alzheimer's disease and osteoporosis. Hence LOX inhibition in chronic conditions can lead to reducing the disease progression, which can be a good target for treating these diseases. The present study deals with designing methyl gallate derivatives and their anti-inflammatory effect by in silico, in vitro and in vivo methods. Designed derivatives were docked against LOX enzyme, and molecular dynamic simulations were carried out. Following the synthesis of derivatives, in vitro LOX inhibition assay, enzyme kinetics and fluorescence quenching studies were performed. One of the derivatives of methyl gallate (MGSD 1) was demonstrated as an anti-inflammatory agent for the treatment of rheumatoid arthritis in the animal model. Amelioration of Freund's complete adjuvant (FCA)-induced arthritis by methyl gallate and its derivative with a concentration of 10-40 mg.kg has been assessed in vivo in a 28-day-long study. TNF-α and COX-2 gene expression were also studied. Methyl gallate synthetic derivatives (MGSDs) inhibited LOX with an IC of 100 nM, 304 nM, and 226 nM for MGSD 1, MGSD 2, and MGSD 3, respectively. Fluorescence quenching methods also prove their binding characteristics, and 200 ns simulations studies showed that the RMSDs for the entire complex were less than 2.8 Å. The in vivo results showed that methyl gallate was required approximately five times diclofenac for the same level of effect, and the synthesised (MGSD 1) compound required only approximately 1/12 of diclofenac for the same level of effect in in-vivo studies. The preeminent expression of COX-2 and TNF-α genes was significantly decreased after the treatment of the methyl gallate derivative. Hence, the in vivo results showed that the referenced synthetic derivative might have more arthritis-reducing properties than the parent compound methyl gallate and is more potent than the standard drug diclofenac, with no apparent induced toxicity.
哺乳动物脂氧合酶(LOXs)参与过敏反应介质的生物合成,并与细胞成熟、支气管哮喘、动脉粥样硬化、类风湿性关节炎、心血管疾病、阿尔茨海默病和骨质疏松症的发病机制有关。因此,慢性疾病中 LOX 的抑制作用可以减缓疾病的进展,这可能是治疗这些疾病的一个很好的靶点。本研究通过计算机模拟、体外和体内方法设计没食子酸甲酯衍生物及其抗炎作用。设计的衍生物与 LOX 酶对接,并进行分子动力学模拟。在合成衍生物后,进行了体外 LOX 抑制试验、酶动力学和荧光猝灭研究。没食子酸甲酯的一种衍生物(MGSD1)被证明是一种治疗类风湿性关节炎的抗炎剂,在动物模型中进行了研究。在 28 天的研究中,体内评估了没食子酸甲酯及其衍生物(浓度为 10-40mg/kg)对完全弗氏佐剂(FCA)诱导关节炎的改善作用。还研究了 TNF-α 和 COX-2 基因表达。没食子酸甲酯合成衍生物(MGSDs)对 LOX 的抑制作用的 IC 分别为 100nM、304nM 和 226nM,用于 MGSD1、MGSD2 和 MGSD3。荧光猝灭方法也证明了它们的结合特性,200ns 模拟研究表明整个复合物的 RMSD 小于 2.8Å。体内结果表明,没食子酸甲酯的效果与双氯芬酸相同,但所需剂量约为双氯芬酸的五倍,而合成的(MGSD1)化合物的效果与双氯芬酸相同,但所需剂量仅为双氯芬酸的 1/12。COX-2 和 TNF-α 基因的显著表达在没食子酸甲酯衍生物治疗后明显降低。因此,体内结果表明,参考合成衍生物可能比母体化合物没食子酸甲酯具有更强的关节炎缓解特性,并且比标准药物双氯芬酸更有效,没有明显的诱导毒性。